#DexCom Patents

[newsmarketreports]

Understanding DexCom Patents: Innovations in Diabetes Technology

Dexcom Inc. is a pioneering company in the field of continuous glucose monitoring (CGM) systems, widely recognized for its commitment to innovation and technological advancement. At the heart of Dexcom's success is its extensive and robust patent portfolio, which protects the company’s cutting-edge technologies and underpins its leadership in the diabetes management industry. This article provides a comprehensive analysis of Dexcom’s patents, highlighting the strategic importance of its intellectual property (IP) assets in maintaining its competitive edge and driving future growth.

To know about the assumptions considered for the study, Download for Free Sample Report

Dexcom Inc.: A Leader in Continuous Glucose Monitoring

Founded in 1999, Dexcom has revolutionized diabetes care through its innovative CGM systems, which allow people with diabetes to monitor their blood glucose levels in real-time. The company’s patented technologies have set new standards in accuracy, convenience, and patient experience, making Dexcom a trusted name in the healthcare industry.

1. The Strategic Importance of Dexcom’s Patents

Protection of Core Technologies: Patents are critical to Dexcom’s business strategy, providing legal protection for the company’s core technologies. These patents cover a wide range of innovations, from sensor design and manufacturing processes to data analytics and wireless communication technologies. By securing patents for its key innovations, Dexcom can safeguard its proprietary technologies from competitors, ensuring that it remains at the forefront of the CGM market.

Barrier to Entry: Dexcom’s extensive patent portfolio creates significant barriers to entry for potential competitors. The company’s patents cover crucial aspects of CGM technology, making it difficult for other companies to develop similar products without infringing on Dexcom’s IP rights. This strong patent protection not only helps Dexcom maintain its market leadership but also supports the company’s pricing power and profitability.

Innovation and R&D: Dexcom’s commitment to innovation is reflected in its ongoing investment in research and development (R&D). The company’s R&D efforts are focused on improving the accuracy, reliability, and usability of its CGM systems. As a result, Dexcom continuously files new patent applications to protect the outcomes of its R&D activities. These patents are essential for Dexcom’s long-term growth, as they enable the company to introduce new and improved products to the market while maintaining a competitive edge.

2. Key Patents in Dexcom’s Portfolio

Sensor Technologies: One of the most critical areas of Dexcom’s patent portfolio is its sensor technologies. These patents cover the design, fabrication, and operation of Dexcom’s glucose sensors, which are the core components of its CGM systems. Dexcom’s sensors are known for their high accuracy and long wear time, which are key differentiators in the market. The company’s patents in this area protect its proprietary sensor designs, ensuring that Dexcom remains a leader in sensor technology.

Wireless Communication: Another important category of Dexcom’s patents relates to wireless communication technologies. Dexcom’s CGM systems rely on secure and reliable wireless communication to transmit glucose data from the sensor to the display device or smartphone app. The company’s patents in this area cover various aspects of wireless communication, including data transmission protocols, signal processing, and power management. These patents are crucial for ensuring the seamless and efficient operation of Dexcom’s CGM systems.

Data Analytics and Software: Dexcom’s patent portfolio also includes a significant number of patents related to data analytics and software. These patents cover the algorithms and software used to analyze glucose data, generate insights, and provide real-time alerts to users. Dexcom’s software innovations are essential for enhancing the user experience and enabling personalized diabetes management. By protecting its software technologies with patents, Dexcom can continue to offer advanced features and functionalities that set its CGM systems apart from competitors.

3. Geographic Distribution of Dexcom’s Patents

United States: The majority of Dexcom’s patents are filed and granted in the United States, which is the company’s largest and most important market. The U.S. patent system provides strong protection for technological innovations, making it a critical jurisdiction for Dexcom’s IP strategy. The company’s U.S. patents cover a wide range of technologies, ensuring comprehensive protection for its CGM systems.

Europe: Dexcom also holds a significant number of patents in Europe, which is another key market for the company. European patents provide protection across multiple countries, allowing Dexcom to secure its innovations in a region with a large and growing diabetes population. The company’s European patents are essential for its ability to compete in the European market and expand its customer base.

Asia-Pacific: The Asia-Pacific region is an emerging market for Dexcom, with significant growth potential. Dexcom’s patent portfolio in this region is strategically important as the company seeks to expand its presence in countries such as China, Japan, and Australia. By securing patents in these markets, Dexcom can protect its innovations and establish a strong foothold in the region’s rapidly growing healthcare market.

4. Recent Patent Filings and Innovations

Next-Generation Sensors: Dexcom continues to innovate in the field of sensor technology, with recent patent filings focused on next-generation sensors that offer even greater accuracy, longer wear times, and improved patient comfort. These innovations are expected to drive the development of new CGM systems that further enhance the quality of life for people with diabetes.

Artificial Intelligence and Machine Learning: Dexcom is also exploring the use of artificial intelligence (AI) and machine learning (ML) in its CGM systems. The company has filed patents related to AI-driven data analytics, which can provide more accurate glucose predictions and personalized treatment recommendations. These technologies have the potential to revolutionize diabetes management by offering more precise and individualized care.

Integration with Other Health Technologies: Dexcom is actively pursuing patents related to the integration of its CGM systems with other health technologies, such as insulin pumps and smartwatches. By securing patents in this area, Dexcom can develop integrated solutions that offer seamless diabetes management and improve patient outcomes. These innovations are likely to become increasingly important as the market moves towards more connected and interoperable healthcare solutions.

5. The Impact of Dexcom’s Patents on Its Market Position

Market Leadership: Dexcom’s strong patent portfolio is a key factor in its market leadership. The company’s patents protect its technological innovations, allowing it to offer superior products that meet the needs of people with diabetes. As a result, Dexcom has established a dominant position in the CGM market, with a large and loyal customer base.

Competitive Advantage: Dexcom’s patents provide a significant competitive advantage by preventing competitors from copying its technologies. This protection allows Dexcom to maintain its leadership position in the market and continue to invest in innovation. The company’s patents also support its ability to charge premium prices for its CGM systems, contributing to its strong financial performance.

Growth Opportunities: Dexcom’s patent portfolio also opens up new growth opportunities for the company. As the global demand for CGM systems continues to rise, Dexcom’s patents enable it to expand into new markets and develop new products. The company’s ongoing innovation, supported by its patents, positions it well for future growth in the rapidly evolving diabetes care market.

Conclusion

Dexcom Inc.’s patent portfolio is a cornerstone of its success in the continuous glucose monitoring industry. By protecting its core technologies and fostering innovation, Dexcom has established itself as a leader in diabetes care. The company’s patents not only provide a competitive advantage but also support its long-term growth strategy. As Dexcom continues to innovate and expand its patent portfolio, it is well-positioned to maintain its leadership in the CGM market and improve the lives of people with diabetes around the world.

[intelacia]

How absolutely necessary CONTINUOUS GLUCOSE MONITORING is ?

Everybody knows about diabetes at this point. It can cause serious damage to several of the body functions mainly marring the nervous and vascular systems. A 300% jump in number of diabetic patients was observed in less than 35 years (According to WHO) and as reported by International Diabetes Federation in 2021, roughly 540 million adults between age 20 – 80 are diabetic. Diagnosis at prediabetic stage and controlling blood sugar levels early-on, greatly diminishes the possibility of advancements to Type 1 and Type 2 diabetes; and glucometer or glucose meter helps monitor blood glucose levels on a regular basis, aiding in maintaining sufficient concentration of sugar or glucose in the blood.

Continuous Glucose Monitoring Systems

Continuous Glucose Monitoring or CGM measures and tracks glucose level continuously, enabling either the patient or the doctor or both, to gain understanding of the trends like spike and fluctuations. CGM supports people by letting them efficiently adapt to variations. It helps in accurate diabetes management and drug prescription for Type 1 and Type 2 diabetes. Lifestyle changes can be implemented effortlessly as well. CGM is facilitated by CGM System that fundamentally are constituted by sensors, transmitters and receivers.

But WHAT exactly is a CGM System?

It is an electronic medical device employed to continuously monitor blood glucose levels in the blood stream day and night, from anywhere between couple of days to couple of weeks. It is a home glucose monitor worn continuously for long durations. It relieves the patients’ trauma of repeatedly pricking their fingers. Traditionally the sensor and transmitter of the CGM system is packaged into a single unit that stays either on the abdomen or arm with adhesives; and the receiver is a handheld device to which the data is transmitted.  

And HOW does it work?

A tiny sensor is placed right under the skin with the help of an applicator. Adhesives on the applicator holds the sensor in-place and prevents accidental dislodging. These sensors measure the concentration of sugar in the body fluids. Usually, the blood sugar level reading is taken every 5 minutes. The CGM sensors are non-reusable and requires replacement. The electronics in the CGM system relays the accumulated blood glucose data, mostly wirelessly, via transmitters to receivers in a handheld electronic device (like a smart watch, digital display or smart phones).

So WHICH one to choose?

As always, the market is flooded with variety of Continuous Glucose Monitors. It is always difficult to choose and trust one’s decision when it comes to medical devices and instruments. The digital device market for diabetes monitoring is eying to reach $12 billion which was $3billion 2018, by 2025.

1. Abbott Freestyle Libre 2

It is 2nd generation continuous glucose monitor developed by Abbott laboratories. It was released in 2020 and addressed certain issues with Freestyle Libre such as interreference due to presence of Aspirin, absence of alarms & alerts and usage approval for only 18 years or older. It is one of the popular CGM system mainly due to its low cost. With Libre 3 on the horizon, thinner and sustainable option, which also claims to have the smallest sensor in the world, will be welcomed. In the last month itself Abbott Diabetes Care Inc. were granted more than 5 patents for CGM related technologies – An automatic sensor insertion device, Connectors for analyte sensor & associated systems and System displays for monitoring devices to name a few; which makes cogent the development of this CGM system is towards lesser inaccuracies.

2. Dexcom G6

G6 is the next iteration of Dexcom G5. Improving on the newer version, the technological aspect has been given importance.  Direct-to-mobile app technology eliminates the need of a separate reader. This also enables real-time monitoring of blood glucose levels. Data sharing capability allows the user to get immediate attention, if necessary. Analyte sensor are not impacted by any medication like acetaminophen or vitamin C. Above all, Dexcom G6 has an automatic sensor insertion applicator.

3.Medtronic Guardian Sensor 3

Developed by Medtronic, being a stand-alone system, unrestricted usage and compatibility with insulin pumps, unchallenging sensor insertion and predictive alerts are some pros of Guardian sensor 3 But requiring extra adhesion, lack of user-friendly design of transmitter & involving many steps to set-up, calibration every 12-hours, 2 hours of warm-up time and comparative higher price point together with false reading reported by users, makes it the most unreliable and difficult to recommend CGM system. According to mean absolute relative difference or MARD (The lower the better) Guardian Sensor 3 landed in the range of 9 – 11 percent.

4.Eversense CGM System

The only, first-of-its-kind CGM system with implanted sensor, with a wear life of 90 days, eliminating the need to replace it very frequently. The transmitter is attached over the implant that can be removed as per the user without damaging the sensor; but which needs adhesive reapplication every 24 hours of continuous use. It has an excellent UI for the mobile app offering range of customizations including personalized sugar level fluctuation alert. As per FDA, it requires calibration once a day and one-time 24 hours long warm-up Eversense 90-day received 8.5% to 9.6% MARD score.

Why DEXCOM G6 is the ultimate CGM?

With a MARD score of 9%, and 9.3% for Freestyle Libre 2, Dexcom G6 is the most precise and accurate CGM system in the market. The lower priced Freestyle Libre 2 attracts potential users but data accuracy and reliability surpasses concerns of financial nature. The continuous fetching of data facilitated by a smartphone along with reported less sensor failures places it over its competition.

[navalvessels]

Medical industry companies are increasingly innovating in fintech

Examination of patent filings shows a growing degree of fintech related applications in the industry over the course of the last year

Examination and innovation in fintech in the clinical area is on the ascent.

The latest figures show that the quantity of fintech related patent applications in the industry remained at 12 in the three months ending Walk - up from five over a similar period in 2021.

Figures for patent awards connected with fintech followed an alternate example to filings - shrinking from 10 in the three months ending Walk 2021 to three in a similar period in 2022.

The figures are assembled by GlobalData, who track patent filings and awards from true workplaces all over the planet. Using literary investigation, as well as true patent orders, these licenses are gathered into key topical regions, and linked to key organizations across different industries.

Fintech is one of the key regions followed by GlobalData. It has been recognized similar to a key problematic power facing organizations in the coming years, and is one of the areas that organizations investing assets in now are supposed to receive benefits from.

The figures likewise give an insight into the biggest innovators in the area.

Johnson and Johnson was the top fintech innovator in the clinical area in the most recent quarter. The organization, which has its base camp in the US, documented six fintech related licenses in the three months ending Walk. That was up from two over a similar period in 2021.

It was trailed by the US based Danaher Corp with two fintech patent applications, the US based Becton Dickinson and Co (2 applications), and the US based DexCom Inc (1 applications).

[redtailhawk19]

Diabetes rant

Been awhile since I posted but I'm just really sick of having to pay x amount to live. I need to vent or the urge to off myself will win and i'm not going to let the assholes win. So ignore if you want I just want to vent. My bg is five hundred currently so yeah. I'm just kinda pissed.

Diabetics in America, type 1 and type 2 have to make do by buying insulin from other companies, paying out of pocket prices that can range from 200 to 1500 for a month supply. Relying on Diabetic Facebook support groups where other Diabetics donate extra supplies, copay cards that only work half the time, and fiancal assistance programs that you only qualify if you're in the lowest possible income bracket. This is the fault of Pharmacy benefit managers, insurance companies, the top three pharmaceutical companies, Eli Lily, sanofi and novonordisk that own the patents. Then all three blame each other for the high price, blame the pbms and insurance companies who into blame each other as well. Fun fact Eli Lily came out with a generic insulin. Insulin lispro it's basically humalog. Not that they have been advertising it, the bastards. I've been told at my pharmacy an out of pocket price of humalog is $546 for a month's supply of vials, what's is insulin lispro's out of pocket price for a month's supply? $180 per vial. Had anyone had any luck finding out what it cost the companies to make their analog insulin? I've been looking for that data for 8 years still haven't come across a legitimate source. I heard once from a novonordisk drug rep that Eli Lily makes one vat of insulin for $50 dollars. Lol representative was trying to make the other company look bad but they all do it. So you have insurances that pick which insulins get to be on their formulary. BCBS for example favors humalog. So good luck unless you're allergic to humalog they will deny any prior authorization for another fast acting. My BCBS ins doesn't care that fiasp and novolog work better for me. Now I'm using humalog u 200 which is working for now thank God. Let's now get started on Continuous Glucose monitors, dexcom g6, freestyle libre and guardian sensors.

Having a CGM literally saved my life, I have a 'good insurance plan' I have an 800 dollar deducible, 5000 out of pocket. Met my 800. Dollar ded at the first of the year. Wanna know how? I had to drop $1000 to pay for a 3 month supply of dexcom g6. So I met my deductible so now everything is great? Wrong! I still have to pay %20 coins. So if I want 3 month supply I have to pay $367 dollars of my portion. I don't know about most people but I find it difficult to come up with that sort of lump sum of cash. It's September and I'm only 2000 in on my 5000 out of pocket. Why because I don't go to the doctor unless I have no other choice. I have enough trouble just paying for my diabetic supplies let alone the copays, and remaining balance left over at the end of doc visits. Only doc I see regularly is my Endo. Then BCBS had the gall to keep making me use dme (durable medical equipment) companies that charge a hell of a lot more than pharmacy benefits do. Supposedly bcbs is going to let commerical insurance patients use pharmacy benefits in October so if you have BCBS and use a dexcom CGM have your doc or Endo send prescription to community Walgreens who also has a $120 coupon.

Freestyle libre is at least trying to do something, funnily enough because they market their CGM as a meter and for type two diabetes. Out of pocket price is 75 using e vouch for a month supply, sensors last 14 days, 1 hour warm up time, no alarms but they are working on it. You can use a smart phone and save some money by not getting a reader. Guardian don't know much about but I tried one and sensor died on day one. If the senors work then it does have some advantages. transmitter lasts a year and is rechargable, and you can restart sensor fairly easily.

Pumps Omni pod, tandem and Medtronic.

Gotta Omni pod hands down even though I got a tandem tslim x2 pump. Omni pod is tubeless, Omni pod pods can be potentially pharmacy benefits. So go omnipod also because you can hack the classic pump with the open aes algorithm and get a artifical pancreas because #we aren't waiting. FDA approval takes forever!

Good news on dexcom front, G7 supposedly will come out in end of 2020. It will last fifteen days, 1 hour wait time and transmitter is inside senors so you throw whole unit away. Why is it going to be less expensive? They want to market it towards type 2s.

Did you know you can restart dexcom g6 transmitters and senors. Well you can check out YouTube for fellow Diabetics' instructions. It will save you money and stick it to the assholes trying to monetize diabetes.

It sickens me that Sir Fredrick Banting and his cohorts sold the patent for insulin for a dollar each, total sale being $4 dollars to Ontario college. They sold it so it would be affordable and accessible for everyone.

Back in 1942 Eli Lily and two other companies got in trouble for price fixing insulin. What's the difference between then and now? The government actually did its job and stepped into to stop them.

Everyone who price gouges insulin and Cgms and pumps should be ashamed.

I'm sick of being taken advantage of for an autoimmune disease I don't have a choice in. I'm pissed. I want justice.

I want a healthcare system that won't bankrupt me. I want a system that actually focuses on preventive care and not being for profit. Fun fact our healthcare has not always been for profit. You can thank president Nixon for that.

"Nixon signed into law, the Health Maintenance Organization Act of 1973, in which medical insurance agencies, hospitals, clinics and even doctors, could begin functioning as for-profit business entities instead of the service organizations they were intended to be."

Also fun fact that is when the big top three insulin producers starting raising the prices of insulin and they haven't stopped since.

So the solution to fix our healthcare system is pretty damned simple. Go back to having it be non for profit.

[techsciresearch]

Saudi Arabia Glucometers Market to Grow with an Impressive CAGR until 2026

Increasing demand for diabetes diagnosis and treatment the growth of Saudi Arabia Glucometers Market, in the forecast period.

According to TechSci report, “Saudi Arabia Glucometers Market By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique (Invasive v/s Non-Invasive), By Type (Wearable v/s Non-Wearable), By Distribution Channel (Hospital Pharmacies, Retail Outlet, Online, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Home Care, Others), By Region, Competition Forecast & Opportunities, 2026”, Saudi Arabia glucometer market is expected to expand its market share in the upcoming five years, on the account of rising prevalence of diabetes among the geriatric population of the country. Moreover, the population is more aware about the availability of the glucometer to monitor their blood glucose level and keep a complete check over the records such that patients are able to contact their doctors and consult them in case of any serious event. These factors are driving the growth of the Saudi Arabia glucometers market in the upcoming five years, until 2026.

Glucometers are the blood sugar monitoring devices that helps the patient in keeping check over blood glucose level and makes the intended balance between food habits and exercising. The device keeps a track of all the schedules regarding eating and medicinal dosage, diet and exercises. The glucometers are widely available through online distribution channel and pharmacy stores. The device is often consisting of a lancet that pricks the finger and draws blood, this blood is added onto the strip which is then connected to the detector or the smart phones that supports the application that records the blood sugar level. The device is used in hospitals and at home by the patents personally.

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on"Saudi Arabia Glucometer Market"

https://www.techsciresearch.com/report/saudi-arabia-glucometers-market/7402.html

The Saudi Arabia glucometer market is segmented by product type, type, technique, distribution channel, end user, regional distribution, and competitive landscape. Based on type the market is further fragmented into wearable and non-wearable glucometers.

Wearable glucometer is anticipated to register the fastest growth in the market owing to the surge in demand of the product and by the rising number of the diabetic patients that demand better devices and technologically advanced options for their regular blood sugar monitoring. Non-wearable glucometers are expected to hold the significant share of the market owing to their ease of availability and smartphone compatibility, thereby supporting the growth of the market in the upcoming five years.

Diabetes is a chronic condition that arises due to irregular blood sugar levels in the body. The treatment often involves insulin hormone treatment that regulates the sugar level in the human body. Glucometers are used to consistently monitor the blood sugar level on daily, weekly, or continuous period. There are various types of devices available in the market that vary in sizes, prices, length of testing time, ease of accessibility.

In March 2020, the country was affected by the widespread of COVID-19 like the whole world. The economies were affected and the whole world observed a complete lockdown. This affected the market although the healthcare industry was functional as per requirement. Due to the increased number of COVID positive patients, general patients were not able to obtain the due treatments. This resulted in increased sales of self-monitoring devices. Thus, it can be considered as one of the major factors that boosted the growth of Saudi Arabia glucometers market and is expected to do in the next five years as well.

Some of the top players in the Saudi Arabia glucometers market are, Abbott Saudi Arabia, Roche Diagnostics Saudi Arabia LLC, Batterjee National Pharmaceutical (Contour-Ascensia), VitalAire Saudi Arabia, Zimmo Trading Co. Ltd. (Omron Healthcare), Platinum Equity (LifeScan), Johnson & Johnson Medical Saudi Arabia Limited, Dexcom Saudi Arabia, Medtronic Saudi Arabia, Sanofi Aventis Arabia Co. Ltd., among others. The companies are involving themselves into research and development for the methods of better quality, to provide better products.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7402

Customers can also request for 10% free customization on this report.

“Kingdom of Saudi Arabia supports a large population with disposable incomes. The increased concerns over the deteriorating lifestyle and thus caused diabetes and the related problem is driving the market growth. Moreover, the technologically advanced products can be seen as the future of the glucose monitoring devices. The devices with the smartphone compatibility are a major reason behind the surge in the demand. New players may form a partnership or work on the development of well researched and technologically advanced medical devices that will be cost effective as well as efficient with added functions,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Saudi Arabia Glucometers Market By Product Type (Self Glucose Monitoring Glucometers v/s Continuous Glucose Monitoring Glucometers), By Technique (Invasive v/s Non-Invasive), By Type (Wearable v/s Non-Wearable), By Distribution Channel (Hospital Pharmacies, Retail Outlet, Online, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Home Care, Others), By Region, Competition Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia glucometers market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Saudi Arabia glucometers market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Web:   https://www.techsciresearch.com/

[fostermarketarch]

Continuous Glucose Monitoring Device Market Prominent Growth And Vendor Landscape By 2027

Foster Market Research’s new market research report on the Continuous Glucose Monitoring Device market offers in depth analysis (including revenue analysis for both historic (2018-2020) and forecast periods (2021-2027) for all the market segments. The report is a compilation of various segmentations, including market breakdown by segment 1 (By Intubation), segment 2 (By Type) Segment 3 (By Application).The report also highlights a thorough analysis of the market dynamics, comprising factors that either enable or inhibit the overall market growth, along with potential opportunities that can be tapped in the future.

Get PDF Brochure of this Research Report @  https://www.fostermarketresearch.com/product/industry/7/305/Pdf%20Brochure/            

Further, the Continuous Glucose Monitoring Device market report also includes comprehensive assessment of the following factors:

·         Short-term, mid-term, and long-term COVID-19 impact assessment for the Continuous Glucose Monitoring Device market.

·         Detailed market estimations and forecast on the basis of five different regions including North America (U.S. and Canada), Europe (Germany, U.K., France, Italy, Spain, Russia, and Rest-of-Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, ASEAN, and Rest-of-Asia-Pacific), Latin America (Brazil, Mexico, and Rest-of-Latin America) and the Middle East and Africa (GCC Countries, Israel, South Africa, and Rest-of-Middle East and Africa).  

·         Detailed sections focused on different types of segments (By Intubation, By Type, By Application, By End User and By Region)

·         In-depth information about the industry analysis including technological advancements, regulatory and reimbursement scenario, supply chain analysis, patent analysis, pricing analysis, market trends, and PEST and PORTER analysis, among others.

·         Market Share Analysis of key players.

·         Company profiling of more than 10 companies.

 For More Information @ https://www.fostermarketresearch.com/product/industry/7/305/

 The global Continuous Glucose Monitoring Device industry is one of the most competitive industries, with the leading players actively competing against each other to gain a greater share in the industry. The competitive landscape of the Continuous Glucose Monitoring Device industry exhibits an inclination toward emerging strategies and developments by market players.

Some of the key players that are actively participating in the Continuous Glucose Monitoring Device market include: Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., and F. Hoffmann-La Roche Ltd. The major strategies adopted by market players are collaborations, product launches, and product approvals, among others.

 The report is essential for the stakeholders operating in the Continuous Glucose Monitoring Device market, such as emerging start-ups, manufacturers, suppliers, distributors, end users, and investors, to understand the varying supply and demand side factors and the nature of the business with lucrative opportunities to enter into the market.

 How this business report enables organizations to take strategic decisions:

·         Provides go-to market strategies for diversified products present across different segment and geographies

·         Analyzing competitors’ scenario along with their key developments and strategies

·         Analyze end user requirements

·         Aids in discovering newer applications

·         Analyzing technological/product substitutes by comparing the present product specifications

 Key Questions answered in the report:

What are the trends     adopted by key players in the global telemedicine market?

What is the competitive     strength of the key players in the telemedicine market?

What are the major     outcomes derived from the Porter’s five forces?

What are the major     challenges inhibiting the growth of the global telemedicine market?

Which end user contribute     highest CAGR (%) in the telemedicine market?

Buy Now This Premium Report To Grow Your Business @ https://www.fostermarketresearch.com/product/buy/7/305/

 About Foster Market Research:

Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.

Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.

Contact Us: 1701 royal lane, #1306, Dallas Tx-75229

Phone: +14694981929 Email: support@fostermarketresearch.com

[sandlerresearch]

Wearable Healthcare Devices Market by Type (Diagnostic (ECG, Heart, Pulse, BP, Sleep), Therapeutic (Pain, Insulin)), Application (Fitness, RPM), Product (Smartwatch, Patch), Grade (Consumer, Clinical), Channel (Pharmacy, Online) - Global Forecast to 2025 published on

https://www.sandlerresearch.org/wearable-healthcare-devices-market-by-type-diagnostic-ecg-heart-pulse-bp-sleep-therapeutic-pain-insulin-application-fitness-rpm-product-smartwatch-patch-grade-consumer-clinical.html

Wearable Healthcare Devices Market by Type (Diagnostic (ECG, Heart, Pulse, BP, Sleep), Therapeutic (Pain, Insulin)), Application (Fitness, RPM), Product (Smartwatch, Patch), Grade (Consumer, Clinical), Channel (Pharmacy, Online) - Global Forecast to 2025

“Wearable healthcare devices market to register a CAGR of 20.5% from 2020 to 2025”

The global wearable healthcare devices market is projected to reach USD 46.6 billion by 2025 from USD 18.4 billion in 2020, at a CAGR of 20.5%  from 2020 to 2025. The growth of the industry is driven primarily by factors such as increasing awareness of fitness and healthy lifestyles, development of technologically advanced products, growing geriatric population and subsequent increase in the incidence of chronic diseases, cost-containment in healthcare delivery, robust penetration of 3G and 4G networks for uninterrupted healthcare services, increasing penetration of smartphones and the growing number of smart-phone based healthcare apps and growing preference for wireless connectivity among healthcare providers. However, patent protection of wearable healthcare devices, limited battery life and device design complexity may restrict the growth of this market to a certain extent.

“The general health and fitness segment is expected to grow at the fastest growth rate during the forecast period”

Based on applications, the wearable healthcare devices market is segmented into general health and fitness, remote patient monitoring, and home healthcare. In 2019, the general health and fitness segment accounted for the largest share of the market. This general health and fitness segment is expected to be the largest and fastest market segment in 2019. The large share of this segment can be attributed to the increasing focus on physical fitness among people to improve their quality of life, coupled with the growing trend of tracking health progress on a continuous basis.

“Pharmacies segment is estimated to account for the largest share of the wearable healthcare devices market in 2020”

Based on the distribution channel, the wearable healthcare devices market is segmented into pharmacies, online channels, and hypermarkets. In 2019, the pharmacies segment accounted for the largest share of the market with the highest growth rate as well. The market is mainly driven by the increasing trend of self-monitoring and non-invasive monitoring and diagnosis have resulted in a substantial increase in the supply of wearable devices in pharmacies. This is driving the uptake of wearable devices among customers, as they have easy access to various wearable devices offered by a number of companies. Furthermore, pharmacies are widely perceived to sell authentic and reliable products, which has greatly driven consumer preference for this distribution channel. However, online channels are expected to grow at the highest rate during the forecast period, due to the increasing use of smartphones, a large number of online buying apps, and the wide spectrum of devices available online, among other factors.

“Consumer-grade wearable healthcare devices segment is expected to dominate the wearable healthcare devices market during the forecast period.”

Based on grade type, the wearable healthcare devices market is segmented into consumer-grade and clinical-grade wearable healthcare devices. The consumer-grade wearable healthcare devices segment dominated the market. In 2019, the consumer-grade wearable healthcare devices segment accounted for the largest share of the wearable healthcare devices market.Factors such as the increasing trend toward self-monitoring, ease of availability of consumer-grade wearable healthcare devices, and the comparatively low cost of consumer-grade devices as compared to clinical-grade devices are the major factors responsible for the large share of the consumer-grade wearable healthcare devices segment.

“North America  is expected to dominate the wearable healthcare devices market in 2020”

North America, which includes the US and Canada,is estimated to account for the largest share of the wearable healthcare devices market.The large share of this region can primarily be attributed such as the increasing penetration of smartphones, growing geriatric population and the subsequent rise in the prevalence of chronic disorders, increasing healthcare costs, growing demand for better healthcare services, government initiatives to promote digital health, the robust penetration of 3G and 4G networks, and the growing awareness of self-health management.

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (45%), Tier 2(30%), and Tier 3 (25%)

By Designation: C-level (45%), Director-level (30%), and Others (25%)

By Region: North America (35%), Europe (30%), Asia Pacific(25%), Latin America (5%) and Middle East & Africa (5%)

The key players operating in this market include Medtronic plc. (Ireland), Koninklijke Philips N.V. (Netherlands), OMRON Corporation (Japan), Biotelemetry Inc.(US), Apple, Inc. (US), Dexcom Inc. (US), Abbott Laboratories(US), Masimo Corporation(US), GE Healthcare(US), Bio-Beat Technologies (Israel), iRhythm Technologies, Inc. (US), VitalConnect (US), Minttihealth (US), Preventice Solutions, Inc. (US), CONTEC Medical Systems Co. Ltd (China), Biotricity Inc.(US), Verily Life Sciences.(US), Cyrcadia Asia Limited (Hong Kong ), ten3T healthcare (India), Fitbit, Inc. (US) , Garmin Ltd (Switzerland), Xiaomi Technologies (China), and Huawei Corporation (China). Product launches & approval, expansions,  collaborations, agreements,partnerships,and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage

This report studies the wearable healthcare devices market based on the device type, application, product, grade type, distribution channel, and region.  The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total wearable healthcare devices market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the wearable healthcare devices offered by the key 20 players in the wearable healthcare devices market. The report analyzes the wearable healthcare devices market by device type, application, product, grade type, distribution channel, and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various wearable healthcare devices, their adoption, type of applications across key geographic regions.

Market Diversification: Exhaustive information about new product launches & approvals, untapped geographies, recent developments, and investments in the wearable healthcare devices market

Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the wearable healthcare devices market along with a competitive leadership mapping of up to 25 players in the market.

[vibhavaripatil-blog]

Global Portable Glucose Monitor Market is expected to reach US$ XX billion by 2026, at CAGR of X% during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Portable Glucose Monitor dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTER’s analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Portable Glucose Monitor Market.

Overview

Global Portable Glucose Monitor Market has valued US$ XX Bn in 2017 and is expected to reach US$ XX Bn by 2026 at a CAGR of XX % during the forecast period. According to the International Diabetes Federation, around 425 Million people are suffering from diabetes as of 2017 worldwide and are going to be 642 million people with diabetes by 2040. The change in the lifestyle of the people led to an increase in the number of diabetic patients worldwide which will help the growth of this market over the forecast period. The portable glucose monitor helps us to keep a check on blood glucose levels which is vital for proper diagnoses and treatment of diabetes. This equipment is the near-patient devices that allow the immediate detection of glucose levels in the body of a patient and facilitate rapid treatment solutions if the need arises.

By Segment Analysis

Based on type, there are two types of portable glucose monitor they are wearable and non-wearable. And based on components, it is divided into glucometer device, test strips, and lancets. In 2018, North America accounts the largest market share of the global portable glucose monitor market rapidly increasing obese population, payable to early acquisition of these solutions and presence of key players in the region. The Asia-Pacific is expected to witness to make the largest market share during the forecast period.

Drivers and Restraints

The drivers of the global portable glucose monitor are the various public and private initiatives to reduce diabetic cases, tremendous development potential owing to continues technological advancement in these devices, the convenience of continuous sugar monitoring over conventional monitoring, the rapid increase in aging population and hyperglycemic diabetes. On the other hand, various factors challenging industry growth such as high cost related to the diagnosis of diabetes, inadequate reimbursement related to the application of CGM systems and patent expiry issues and product recalls are some of the key factors obstruct the market growth.

Scope

• Glucometer Device

• Test strips

• Lancets

by Type

• Wearable

• Non-Wearable

by End-user

• Hospitals and diagnostic laboratories

• Physician Office Laboratories

• Home-care settings

by Region

• North America

• Europe

• Asia-Pacific

• Middle East & Africa

• South America

Key Players

• Abbott Diabetes Care

• Roche

• Johnson & Johnson (Lifescan)

• Dexcom

• Medtronic

• Arkray

• Ascensia Diabetes Care

• Agamatrix Inc.

• Bionime Corporation

• Acon

• Medisana

• Trivida

• Rossmax

About company

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

[vynzresearch-blog]

Blood Glucose Monitoring System Market Outlook, Worldwide Estimates, Trends and Forecast 2024

Industry Overview

Diabetes mellitus is a group of chronic endocrine gland disorder due to the insufficient level of insulin supply. Prolonged hyperglycemia (high blood sugar) can lead to severe complications including cardiovascular disease, kidney failure, diabetic retinopathy or nephropathy, and ulcers. Blood glucose monitoring systems help patents to the testing of blood glucose level in the body. The global blood glucose monitoring system market is growing at a significant pace due to the increasing prevalence of diabetes cases globally. The market is expected to grow at a significant rate for continuous blood glucose monitoring products in the coming years due to the growing adoption of minimally invasive procedure.

Request for Free Sample Copy of this Research Report at: https://www.vynzresearch.com/healthcare/blood-glucose-monitoring-system-market/request-sample

Market Segmentation

Insight by Product

Currently, there are two types of blood glucose monitoring system, self-monitoring blood glucose systems, and continuous monitoring blood glucose system. As both the types the continuous monitoring blood glucose system market is expected to grow at the higher growth rate, as in increasing adoption of minimally invasive procedure.

Insight by Testing Site

By the basis of the testing site, the blood glucose monitoring system market is segmented into fingertip testing and alternate site testing. Among the most common technique used for measurement of blood glucose level is Fingertip testing. Globally Fingertip testing segment has a larger share and is also expected to grow at a faster rate due to high reliability and accuracy of fingertip testing.

Insight by Application

The worldwide blood glucose monitoring system market has also been further segmented by application into type I, type II and gestational diabetes. Type I diabetes accounts for about 5 to 10 percent of the diabetes cases and type II accounts for approximately 90 percent of the diabetic cases. Many patients with type II diabetes are asymptomatic. The type II diabetes segment is estimated to have the biggest share in the market due to the growing incidence of type II diabetes and increasing innovative product launches with less invasive technologies. According to the International Diabetes Federation (IDF) in 2017 approximately 352 million people were at risk of developing type II diabetes.

Insight by Patient Care Setting

The end-applicant of the blood glucose monitoring system market are hospitals and clinics, and home care. The home care segment has the biggest share and likely to grow at the fastest rate due to a rising diabetic population, increasing innovative product launches enhancing patient comfort and increasing awareness of regular monitoring of glucose levels.

Industry Dynamics

Growth Drivers

The growing prevalence of diabetes, speedy increase in the aging population and the increasing number of product launches are the primary growth drivers for blood glucose monitoring system market. As per the World Health Organization (WHO), the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. In pipeline products, developments and ongoing researches and increasing adoption of the continuous sugar surveillance system are also driving the global market. Due to technological advancement in glucose monitoring is making device smaller, smarter and more convenient.

Challenges

The high cost of blood glucose monitoring products, invasiveness of blood glucose monitors and poor reimbursement of blood glucose monitoring devices and supplies are the major challenges for the growth of blood glucose monitoring system market. In developing countries like Africa and some Asian countries, it is difficult to bear the cost of the testing strips and blood glucose monitors due to poor reimbursement policies. However, in some of the developed countries like Europe and in Canada, the limitation on the supply of testing strips per patient hinder the growth of the market.

Industry Ecosystem

The robust distribution channel for blood glucose monitoring products helps to cater to the increasing demand for diabetic care device. The main challenge for the new entrants is the survival in capital intensive and highly regulated blood glucose monitoring system market.

Geographic Overview

Globally, North America is the largest blood glucose monitoring system market as the region has favorable reimbursement policies, increasing awareness program and rising FDA approvals. An increasing prevalence of diabetes has powered the growth of the North American blood glucose monitoring system market. According to the Centers for Disease Control and Prevention (CDC), in 2015, approximately 23.1 million people in the U.S. had diabetes.

Browse Full Research Report Description at: https://www.vynzresearch.com/healthcare/blood-glucose-monitoring-system-market

Asia-Pacific, especially in countries like India, Japan, China, Korea, Thailand, is observed to witness the fastest growth in demand for blood glucose monitoring products. The increasing prevalence of diabetes, growing awareness of diabetes, increasing healthcare expenditure, and the huge population base is creating a positive impact on the blood glucose monitoring systems market growth in the region.

Competitive Insight

Main players in the blood glucose monitoring system market are investing in the development of innovative and advanced products, which is strengthening their position in the market. In September 2016, Abbott gained FDA approval for the FreeStyle Libre Pro continuous glucose monitoring (CGM) device, a professional-use device to provide better diabetes management to a diabetes patient. In addition, in August 2016, Roche launched the Accu-Chek Guide, the next-generation blood glucose monitoring system. Abbott Laboratories, B. Braun Melsungen, F. Hoffmann-La Roche, Ypsomed, LifeScan, Medtronic, Ascensia Diabetes Care, Dexcom, Nipro and Sanofi are the key players offering blood glucose monitoring products.

About VynZ Research

VynZ Research is the leading research and advisory company. We’ve grown well beyond our leading technology research to provide management across the enterprise with the vital information, advice and tools they need to achieve their goal/mission-critical priorities and build the organizations of future.

Together with our customers, we fuel the future of business so that a more successful world takes shape.

Contact

Kundan Kumar

Manager: Client Care

VynZ Research

Direct: +919960288381

Toll-Free:1-888-253-3960

Website: https://www.vynzresearch.com

Email: support@vynzresearch.com

Connect With us: LinkedIn | Twitter | Google | Facebook

[jaimemidulceguerrero]

MENLO PARK, CA – 14 de noviembre de 2018 – Beyond Type 1, organización mundial sin fines de lucro celebra el cumpleaños 127 de Sir Frederick Banting con una fiesta de cumpleaños digital durante el Día Mundial de la Diabetes el próximo Miércoles 14 de noviembre. Una coalición de más de 50 organizaciones se une para trabajar y romper el Récord Mundial de mayor número de contribuciones en una tarjeta electrónica. Firma y participa en BantingsBirthday.org.

La cifra por superar es de 65,402, y el récord le pertenece a Chevrolet, SAIC-GM (China) y fue establecido en 2017 en Shanghai. Las contribuciones para el intento por romper el récord mundial serán deseos de Feliz Cumpleaños para Frederick Banting, a quien se le atribuye el descubrimiento de la insulina, un medicamento que salva la vida de millones de personas con diabetes y que requieren insulina (tanto diabetes Tipo 1 como diabetes Tipo 2).

Antes del descubrimiento realizado por Banting y su colega para uso terapéutico, el diagnóstico de diabetes Tipo 1 era una sentencia de muerte. Desde este descubrimiento en 1921, millones de vidas han sido salvadas día a día gracias a Sir. Frederick Banting y su equipo de trabajo.

Beyond Type 1 es anfitrión de la fiesta digital de cumpleaños y la firma de la tarjeta electrónica en BantingsBirthday.org. “Los invitados de la fiesta” y fans de Banting podrán firmar la tarjeta electrónica de cumpleaños , ingresar para recibir artículos y leer historias sobre el ganador del Premio Nobel. Además, se invita a la comunidad a realizar un donativo de $1 USD en honor al costo de ventas de la patente original, enfatizando la creencia de Banting de que la insulina le pertenecía al mundo.

El intento por romper el Récord Mundial se compartirá por una lista robusta de organizaciones sin fines de lucro que incluye a 1MD, la Asociación Americana de Educadores en Diabetes, CarbDM, Children With Diabetes, Companion Medical, ConnecT1D, Children and Young People’s Diabetes Network Wales, Dexcom, Diabetes NSW, Diabetes NZ, Diabetes Queensland, Diabetes Research Connections, Diabetes Research Institute, Diabetes Sisters, Diabetes Strong, Diabetes Daily, Diabetic Supply UK, Diabetes Patient Advocacy Coalition, Dr. Comfort, Dr.’s Remedy, Genteel, Honey Stinger, The Human Trial, Life For a Child, Livongo, Mannkind, MedAngel, Medtronic Diabetes, Myabetic, MySugr, No Small Voice, NPM, OneDrop, Rhone, Sonia Nabeta Foundation, SpiBelt, Sproutel, Sun Basket, T1D Exchange, Tandem Diabetes Care, Tidepool, Generation UCAN, y We Are Diabetes.

Para mayor información sobre Sir Frederick Banting, sobre la celebración o sobre cómo ayudarnos a romper el récord mundial, visite BantingsBirthday.org.

CONMEMORA EL DÍA MUNDIAL DE LA DIABETES  TRABAJANDO POR ROMPER UN RÉCORD MUNDIAL MENLO PARK, CA – 14 de noviembre de 2018 - Beyond Type 1, organización mundial sin fines de lucro celebra el cumpleaños 127 de Sir Frederick Banting con una fiesta de cumpleaños digital durante el Día Mundial de la Diabetes el próximo Miércoles 14 de noviembre.

[sporadicwinnersong]

Apple and Amazon’s moves in health signal a coming transformation#MohnishAhluwaliaNotes

The world’s biggest tech firms see an opportunity in health care, which could mean empowered patients, better diagnosis of disease and lower costs THE past decade has seen the smartphone become a portal for managing daily life. Consumers use their pocket computers to bank, buy and befriend. Now this array of activities is expanding into an even more vital sphere. Apple has spent three years preparing its devices and software to process medical data, offering products to researchers and clinical-care teams. On January 24th it announced the result. The next big software update for its iPhone will include a feature, Health Records, to allow users to view, manage and share their medical records. Embedded in Apple’s Health app, the new feature will bring together medical data from participating hospitals and clinics, as well as from the iPhone itself, giving millions of Americans direct digital control of their own health information for the first time. Apple’s fellow tech giants are also on the march into medical services. On January 30th Amazon announced a partnership with Berkshire Hathaway and JPMorgan Chase to create a not-for-profit health-care company for their own employees that promises to employ technology to provide cheaper care than conventional health insurers offer. For the past year, the e-commerce giant has also been exploring a venture to use its logistical prowess to start selling drugs online. Alphabet, Google’s parent, has just launched a third health-care firm, Cityblock Health, to operate alongside Verily, a subsidiary based in San Francisco, and DeepMind Health, an arm of its London-based artificial-intelligence (AI) firm (a fourth company, Calico, is working to extend human lifespans, but does not provide health-care services). Alphabet already claims to be able to use AI to predict possible deaths of hospitalised patients two days earlier than current methods, for instance, allowing more time for doctors to intervene. Facebook and Microsoft are preparing to add health care to their core businesses of social networking and software. Until now the tech giants’ foray into health care has not gone much beyond wearable devices to track fitness or the provision of cloud-computing services to incumbent providers. In future they aim to deliver real medical services that directly affect individual patients. All five firms have secretive health-care skunk works, are hiring medical talent and are buying or backing external health-care startups. Undeterred by recent claims that their own products may be harmful to mental health, they want not only to be indispensable in customers’ lives but to prolong them, too. The revenues of the industries they could disrupt are enormous. Health-care costs make up about a tenth of any country’s GDP on average, worth in total $7trn in 2015, according to Deloitte, a consultancy. Two insurers, UnitedHealth Group and CVS Health, are among America’s largest firms by revenue, bringing in $185bn and $178bn respectively in 2016. That is more than any tech firm except Apple. Shares in the two insurers fell by 4% on the news of the new Amazon-led health venture. Apple and Alphabet, however, are likely to have the biggest impact in the near term. Amazon’s three-headed health-care venture will cover roughly 1m employees in the first instance, whereas Apple and Alphabet have the potential to generate or enable valuable health insights for hundreds of millions of users, collecting a small slice of that value in return. There are two broad routes into health care. The first is doing business with hospitals and health-care companies in the existing system. Alphabet provides software services to hospitals, for example; Apple sells smartphones, tablet computers and wearables to medical professionals and hospitals. A second route is for tech firms to use their various platforms to create entirely new channels through which medical care can be delivered to patients. Such channels include watches that use machine-learning algorithms to monitor the wearer’s health, phones through which clinical trials can be run and apps that provide medical-grade care to people managing chronic conditions such as diabetes. Deploying bedside manner Start with the existing system. Alphabet’s business here comes through Verily and DeepMind, and has focused on Britain’s National Health Service, which offers a single, standardised market. DeepMind has partnerships with four large hospital groups, to which it provides an app called Streams. This uses the hospitals’ data to generate alerts that draw doctors’ attention to the potential deterioration of patients. In May, meanwhile, Verily switched on data processing for a hospital—the NHS Heywood, Middleton and Rochdale Clinical Commissioning Group, near Manchester. It crunches through the hospital’s pseudonymised patient records, looking for patterns that suggest the emergence of long-term diseases like diabetes and alerting doctors if they are found. (In September Microsoft started a health-care division in Cambridge, which will devise medical algorithms of its own.) None of this is straightforward. Health records generated in conventional clinical settings are immensely valuable—no amount of smartwatch accelerometer data is going to take the place of an MRI or an X-ray. Such records are increasingly available in digital form (see chart) but they are often messy and hard to process. DeepMind has had to spend months cleaning up data flows from a British hospital, the Royal Free, for instance, and has not yet delivered any AI-driven insights Apple’s approach is more focused on hardware. It is working to make its devices into trusted, secure channels through which medical data can flow. Third parties, rather than Apple itself, then build useful health services on top. Putting patients’ health records on iPhones will make these far more effective. Millions of people around the world have already joined medical studies using this infrastructure, participating through iPhones. Hints are emerging of the power of the approach. An app called mPower, built by Sage Bionetworks, a non-profit research organisation, studies Parkinson’s disease by getting iPhone users to perform tasks and measuring the tremor in their hands using the phone’s internal accelerometer. The data so far suggest that Apple’s platform may soon enable medics to spot Parkinson’s digitally, over the internet, before it is symptomatic in a patient. All this makes money for Apple by increasing the perceived value of its devices, says Anurag Gupta, a health-care analyst at Gartner, an IT research firm. The firm also hopes that clinicians and insurers will buy and use Apple devices in their work. Algorithms v arrhythmia Delivering medical services through brand-new channels—the second route into the industry—holds equal promise. The new non-profit venture from Amazon, Berkshire Hathaway and JPMorgan Chase fits into this category. Details are scarce, but the three firms might, for instance, use Amazon’s data-processing skills to build tools to monitor and care for patients outside hospitals and surgeries. Some speculate that the firms might build an app that makes booking a doctor’s appointment as easy as reserving a table at a restaurant. Whatever is built for their own employees, it seems likely that the services will end up being made available to the public, too. Another recent innovation is Alphabet’s Cityblock Health. Its mission to care for low-income city-dwellers in their own homes does not rely on existing health infrastructure at all. It plans to send its own health-care professionals to the homes of people needing care, with the visits paid for by insurance, often Medicaid, the social-insurance system that covers America’s poorest. Cityblock Health will trawl data to spot where care is needed. It plans to hire some 55 people over the next six months, including data scientists, software engineers and a lead physician, as well as a team to interact directly with patients. Smartphones and watches are channels for new services in their own right. In this realm, Apple would become a direct provider of actual care to patients. It holds patents to turn its phones into full medical devices, using a bundle of sensors around the camera to let users measure their blood pressure, body fat and heart function by pressing a finger to the screen, for instance. Other patent filings envisage putting sensors into both phones and smartwatches to collect electrocardiograms to monitor heart health more precisely, and even doing biometric monitoring through AirPods, the firm’s wireless headphones. Apple has also tinkered with sensors which gauge stress or measure blood oxygenation, and is reportedly working on ways to measure blood glucose through its watch, helping it get a handle on diabetes. Late last year it said it would join up with Stanford University to develop algorithms to spot irregular patterns in heartbeat data gathered by its watch. This research could produce what is known as a “digital therapeutic”, which goes through a full regulatory approval process. Verily’s eclectic range of ventures includes building new kinds of surgical robots in a joint venture with Johnson & Johnson, a drug firm. It is also working on cutlery containing self-stabilisation technology, to help those with tremors to eat. The firm has two joint ventures to try to tackle diabetes, one with Dexcom, a medical-device-maker, and another with Sanofi, a drugs company. Verily also seeks to organise health information so that it can be queried for useful insights. Project Baseline, a research study, will gather data from 10,000 people over four years to do this. Facebook’s work in the field has been discreet and focused on two areas—mental health and clinical trials. In November the firm said it had started to use AI to monitor its users’ online behaviour for patterns which indicate depression, and to reach out in an effort to prevent suicide. The photos a user posts on Instagram may signal depression, for example, depending on the colours they contain, the times at which they are posted and whether they show faces. Google is trying something similar. Facebook is also hoping to formalise and monetise an activity which is already common on its platform—namely, groups of patients discussing their symptoms. One plan is to help drug companies recruit people from these online gatherings for clinical trials, and to manage groups of patients who sign up, presumably in return for payment from the drug firms. This time may be different It is worth remembering that the prospect of technology firms transforming health care has been heralded in the past, only to disappoint. Google started a health-records initiative in 2008, but shut it down by 2011, citing poor adoption. Microsoft made similar efforts with similarly low take-up. Yet ten years on, the centrality of the smartphone, with its potential to give patients access to their data whenever they want and wherever they are, changes the game. So too does the inexorable logic of the data economy. Data sets that contain information about human health are hugely valuable. At a time when health-care budgets around the world are stretched, payers are desperate for insights that might enable them to cut costs while maintaining quality. The more data the tech firms can handle, the more they will learn about human health, and the better the services they can offer will become. That raises some familiar concerns. Privacy is an obvious one: the tech world’s mindset of “move fast and break things” works less well when it comes to health data. And the same competition issues that dog Google’s search business and Facebook’s social-networking service would arise in health care, too, if a particular AI diagnosis platform, say, were to became dominant. DeepMind’s work in Britain is already on the radar of the EU’s competition watchdogs. Meanwhile, Amazon’s partnership with Berkshire Hathaway and JPMorgan Chase will lure in huge quantities of patients’ data, leading to continual improvement of its services and, potentially, fears about dominance. Apple’s entry into the field offers some answers to these worries. Its efforts in health so far have been cautious. The only patient data it processes now come from its partnership with Stanford University, and in future the firm is likely only to analyse medical information from those patients whose trust it has fully secured. Its services will be opt-in; patients who find themselves in hospitals working with Alphabet’s DeepMind, by contrast, are offered opt-out consent mechanisms. Earlier attempts by Google and Microsoft to offer patients a home for their digital records obliged people to consider whether they trusted the two companies enough; many decided the answer was no. If they only have to decide whether their own iPhone is sufficiently secure, many will believe that it is. Apple has so far lagged behind other technology giants in earning revenues from the booming market for data. It may yet strike gold in the most sensitive personal-data category of all.#MohnishAhluwaliaNotes

via Blogger http://ift.tt/2E64KkM

[gloriousdazewombat-blog]

POC Blood Glucose Monitoring Devices Help Improve Diabetes Management

Radiant Insight Announce Addition of New Report “Global and Chinese POC Blood Glucose Monitoring Devices Industry, 2017 Market Research Report”

Description

Growing geriatric population and high prevalence of diabetes is anticipated to drive the demand for POC blood glucose monitoring devices. For diabetic patients, it is essential to monitor glucose molecules in the blood on a frequent basis. Regular glucose monitoring helps in keeping sugar levels under control. Data obtained from monitoring is essential for taking decisions related to insulin dosage, diet, and exercise routine. POC blood glucose monitoring devices are mostly used in clinics, hospitals, homecare settings, and diagnostic centers

 Request Free Sample Copy – https://www.radiantinsights.com/research/global-and-chinese-poc-blood-glucose-monitoring-devices-industry-2017/request-sample

 Sensor Monitoring Devices to Replace Invasive Devices

Major product variants of POC blood glucose monitoring devices are wearable and non-wearable devices. In case of wearable monitoring devices, users can actually wear these devices on their body to measure glucose level. Such devices are usually quite compact in size and are highly advanced in nature. DIA-VIT, SugarBeat, GlucoTrack, and Glucosense Diagnostics are few examples of wearable blood glucose monitoring devices. Most of these devices are non-invasive, which does not require users to prick their finger before use. Generally, non-invasive monitoring devices are equipped with advanced sensors or lasers to generate real-time measurements.

Non-wearable blood glucose monitoring devices, as the name suggests, do not require users to wear them. Selection of wearable and non-wearable devices depends on a patient’s health. If a patient requires continuous blood glucose monitoring, then wearable blood glucose monitoring devices are the best choice. High prevalence of type 2 diabetes is likely to increase the demand for superior monitoring devices. To cater to this demand, a number of manufacturing companies are investing significantly in R&D to design advanced products.  

 For instance, a German company named DiaMonTech has designed an advanced non-invasive medical device to measure glucose level in the blood. The device is equipped with an advanced infrared laser, which can read blood glucose levels within 15 seconds. Users will not be needed to prick their fingers to get required readings. All they need to do is place their finger on a sensor present on the device and their blood glucose readings will be displayed in real-time.

 Market Insights

 Growing number of diabetic patients across the globe is expected to drive the global POC blood glucose monitoring devices during the forecast period (2017-2022), according to a report on Radiant Insights Inc. In addition, increasing adoption of compact non-invasive and innovative products for monitoring glucose levels on a routine basis can augment the growth. Moreover, easy availability of Continuous Glucose Monitoring for Diabetes (CGMS) and Self-Monitoring of Blood Glucose (SMBG) systems in the market is likely to contribute well for the market in coming years

 View Full Report at- https://www.radiantinsights.com/research/global-and-chinese-poc-blood-glucose-monitoring-devices-industry-2017

 Some of the prominent players in the market are Johnson & Johnson; F. Hoffmann-La Roche Ltd; Abbott Laboratories; ARKRAY, Inc.; and Bayer AG; Dexcom, Inc

 About Us

 Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake

 Contact Us

 Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

201 Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States

Tel: 1-415-349-0054

Toll Free: 1-888-928-9744

Mail: sales@radiantinsights.com

Web: http://www.radiantinsights.com

[ramialkarmi]

DIGITAL HEALTH BRIEFING: ASCO's new partnerships aim to improve oncology care — MedStar Health provides digital tools for prenatal care — DarioHealth awarded new patent to improve its offerings

Welcome to Digital Health Briefing, a new morning email providing the latest news, data, and insight on how digital technology is disrupting the healthcare ecosystem, produced by BI Intelligence.

Sign up and receive Digital Health Briefing free to your inbox.

Have feedback? We'd like to hear from you. Write me at: aaouad@businessinsider.com

THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY TO IMPROVE CARE WITH NEW PARTNERSHIPS: The American Society of Clinical Oncology (ASCO) has come to a new license agreement with two digital health start-ups, Tempus and Precision Health AI, to give the firms access to ASCO's massive database of patient records, named CancerLinQ, for an undisclosed sum. Under the agreement, Tempus will use its genomic sequencing technology to transform unstructured data from CancerLinQ into actionable information to be used by physicians and clinics. Precision Health AI will focus on using artificial intelligence and machine learning technology to define cancer datasets for precision treatments and to aid in the development of new cancer drugs.

This will be a significant deal for each stakeholder:

ASCO: The non-profit organization has been extremely effective in securing data, boasting collaborations with over 100 oncology practices nationwide with access to millions of records. However, the firm has struggled to structure this data into effective datasets due to technical and budget constraints. Through this new deal, ASCO's 40,000 members will get the technical tools to make better use of their data and the organization will receive licensing loyalties to further support growth. 

Tempus: This deal will propel the Chicago-based start-up towards its goal of becoming the world’s largest library of cancer care data. On the CancerLinQ database, there are treatment results for roughly 600,000 patients which Tempus will now have access to — this will help the company touch 25% to 30% of cancer patients next year, according to Tempus co-founder Eric Lefkofsky who was cited by Hi-Tech Chronicle. 

Precision Health AI: The firm relies heavily on its machine learning technology for real-time analysis to enable the practice of precision medicine for better cancer patient care. One way to make this technology more accurate is to keep adding data, which drives variance down. Precision Health AI could improve its offerings by leveraging data from the over one million cancer patient records on the CancerLinQ database. 

HEALTH SYSTEM OFFERS DIGITAL TOOLS TO ENSURE HEALTHY PREGNANCY: MedStar Health, a not-for-profit health system in the Maryland and Washington D.C. area, will begin offering pregnant women a kit of digital devices to monitor their pregnancies, according to Healthcare IT News. The bundle will include a connected wireless scale, a wireless blood pressure cuff, and an iPhone app to collect and transmit the data as well as offer tips and guidance to the patients. Using these sorts of connected devices can help healthcare providers ensure that their patients are healthy and aren’t developing any conditions like preeclampsia, a pregnancy disorder that affects 3%-10% of pregnancies worldwide and can be extremely dangerous to the mother and fetus. It’s characterized by the onset of extremely high blood pressure, which most people aren’t equipped to diagnose at home, but which MedStar’s kit could help detect. The kit could also help to reduce the number of routine visits women need to make to their doctor during a pregnancy by allowing some measurements to be taken remotely — women typically visit the doctor every two weeks starting in the third trimester and even more frequently in the final weeks. Other health systems will likely follow suit in order to help reduce costs and limit the number of office visits patients need to make.

DARIOHEALTH PATENTS GLUCOSE MONITOR BATTERY MANAGEMENT: Israeli digital health company DarioHealth announced that it has been awarded a new patent that will allow it to improve the way its connected blood glucose monitoring system minimizes power use and maintains reliable connections, according to the Daily Telescope. DarioHealth’s COO Dror Bacher said that the company is looking to use better battery management techniques to expand compatibility with additional devices. The device is primarily for monitoring blood glucose levels in diabetics. For context, Diabetes affects 29 million people in the US alone as of 2016. DarioHealth is one of many companies developing tech to treat diabetes. For example, Alphabet’s Verily life sciences unit is working with DexCom on creating smaller blood glucose implants, Apple is reportedly attempting to pioneer noninvasive blood sugar measurement, and startups like Glooko are raising capital for diabetes management platforms. 

Enjoy reading this briefing?  Sign up and receive Digital Health Briefing to your inbox.

FLAWS IN PATIENT EXPERIENCE DATA COULD BE HAVING MAJOR IMPACT: George Washington University researchers have found significant flaws in the data being collected to measure the patient experience in emergency departments across the US, according to the Digital Journal. Researchers found that a concrete conclusion could not be made from the patient data being provided due to high variability. They concluded that this was likely a result of very low response rates — response rates came in between 3% and 16% — and the tendency for respondents to only score low or high when taking the survey. Unfortunately for providers, this data is an important indicator in the healthcare industry — for example, this data is used to construct value-based pricing models at hospitals, inform government spending, assess provider performance, and to rank hospitals. Given the potential impact this data can have, providers need to call for new methods to generate reliable data. 

In other news…

The Colorado Mental Health Institute at Pueblo experienced a phishing attack that potentially exposed the health records of 650 patients, according to Healthcare IT News. The breach was the result of employee error — the employee clicked on an email with fake credentials; the hospital is looking into technical safeguards and new training to ensure such a breach will not happen again.

Clew Medical, the Israeli start-up, is launching a predictive analytics platform that uses AI to give medical providers an early warning when a patient's condition is at risk of deteriorating, according to VentureBeat.

Join the conversation about this story »

NOW WATCH: What those tiny rivets on your jeans are for

[healthy-insights]

Diabetes Devices and Drugs Market Research Report: Forecast up to 2019

The global diabetes devices and drugs market will expand at a moderate CAGR of 5.90% during the forecast period from 2013 to 2019, according to a report from Transparency Market Research (TMR). This report is titled “Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019”. In 2012, the global diabetes devices and drugs market was worth more than US$54.0 bn and by 2019, the market is projected to be worth US$83.0 bn.

 Browse the full Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 report @

https://www.transparencymarketresearch.com/diabetes-devices-market.html

 The global diabetes devices and drugs market is driven primarily by the expanding diabetic population around the world. In 2014, the global prevalence of diabetes was recorded to be 9% among adults of age 18 years and older, says the WHO. In addition to this, extensive R&D activities are resulting in turnaround changes in the global diabetes devices and drugs market. The global diabetes devices and drugs market will also benefit from the increasing technological innovation and the rising demand for self-monitoring and insulin delivery devices.

 Request to download and view full ToC -

https://www.transparencymarketresearch.com/report-toc/14

 However, there are certain hurdles that will suppress the growth of the market. These include: Unfavorable reimbursement policies, patent expiry, depleting profit margins, high diagnosis and treatment cost, and hard entry barriers discouraging new players from penetrating the market.By device type, the global diabetes devices and drugs market is divided into diabetes monitoring and diagnostic devices (continuous glucose monitoring devices, analog glucose meters, glucose test strips, lancets and lancing devices, and others) and insulin delivery devices (insulin injectors, insulin pumps, insulin pens, and insulin syringes). By 2019, the segment of test strips is projected to emerge as the leading segment. On the other hand, the segment of continuous glucose monitoring devices is expected to demonstrate the fastest growth during the forecasting horizon.

Therapy-wise, the global diabetes devices and drugs market is segmented into insulin, non-insulin injectable anti-diabetes drugs, and oral anti-diabetes drugs. Long-acting insulin derivatives held a share of 42.7% in the global diabetes devices and drugs market in 2012. Among oral anti-diabetes drugs, the SGLT-2 inhibitors segment will witness a remarkable CAGR of 76.80% during the forecast period.

 Request to view Sample Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

 On the basis of geography, the global diabetes devices and drugs market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America is leading the global diabetes devices and drugs market due to the growing diabetic population and rising demand for novel devices and high-quality drugs. Nevertheless, it is Asia Pacific that is projected to witness the highest growth during the forecast period. The Asia Pacific diabetic devices and drugs market will be driven by its rising diabetic population, growing awareness regarding self-monitoring of diabetes, elevated medical expenditure, and rising penetration of healthcare technology.

Players in the global diabetes devices and drugs market will benefit from the opportunity presented by the development of new formulations of insulin. Moreover, development of non-invasive diabetes diagnostic and drug delivery devices will offer new market leads. The most established players in the global diabetes devices and drugs market are Abbott Laboratories, B. Braun Melsungen, AstraZeneca, Bayer HealthCare, DexCom, and Eli Lilly and Company.

 Diabetes Devices and Drugs Market Report is available @ US$ 5795

https://www.transparencymarketresearch.com/checkout.php?rep_id=14&ltype=S

 About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

 US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[kdmarketresearch]

U.S. Next Generation Diabetes Therapy and Drug Delivery Market – Top players Abbott Laboratories,Echo Therapeutics, Inc.,F. Hoffmann-La Roche Ltd, GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannKind Corporation, Dexcom, Inc, Senseonics Holding, Inc.

KD Market research has presented a detailed report on  “U.S. Next Generation Diabetes Therapy and Drug Delivery Market ” which includes the major application, advantages, and key market trends that are fostering the growth of the market during the forecasted span of 6 years. The research takes a step forward and analyzes the key competitors and global regions that are holding the market share of U.S. Next Generation Diabetes Therapy and Drug Delivery Market  in terms of revenue.

Request for sample@ https://www.kdmarketresearch.com/sample/3441

The U.S. next generation diabetes therapy and drug delivery market was valued at $446 million in 2015, and is estimated to reach $6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023. Next generation diabetes therapy and drug delivery devices are used to accurately check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems such as oral and inhalable insulin help to introduce insulin into the patient?s body without causing pain and also reduces the risk of skin irritation due to frequent use of needles.

The U.S. next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and region. The product type segment includes inhalable insulin, oral insulin, insulin patch, continuous glucose monitoring systems (CGMS), and artificial pancreas. Based on demographic, the market is bifurcated into adult population (>14years) and child population (=14years). Based on indication, the market is divided into diabetes I and II. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare.

Rise in the number of diabetic cases and the benefits of using these advanced devices over conventional products boost the market growth. The well-established healthcare infrastructure and high R&D activities for the advancement in diabetes therapeutic technology are expected to provide opportunities for market growth. However, less variability in products and cost restraints among low and middle-income population are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients in the U.S. are projected to help to open new doors for the growth of the next generation diabetes therapy and drug delivery market.

KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities. The market estimations provided are based on comprehensive analysis of the key developments in the industry. The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indications, and end user. The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type Inhalable Insulin Oral Insulin Insulin Patch CGM System Artificial Pancreas

By Demographic Adult Population (>14 years) Child Population (=14 years)

By End User Diagnostics/Clinic ICU Home Healthcare

KEY PLAYERS PROFILED Abbott Laboratories Echo Therapeutics, Inc. F. Hoffmann-La Roche Ltd. GlySens Incorporated Medtronic Plc Sanofi Novo Nordisk MannKind Corporation Dexcom, Inc. Senseonics Holding, Inc.

The other players of the catheters market include (companies not profiled in the report): Synertech Zosano Pharma Corp. Relmada Therapeutics, Inc. Eli Lilly and Company Enteris BioPharma Transdermal Specialties Inc

browse full report with toc@ https://www.kdmarketresearch.com/report/3441/us-next-generation-diabetes-therapy-and-drug-delivery-market-amr

Table of content

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets 3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year 3.2.2. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA

3.4. REIMBURSEMENT POLICIES 3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring 3.5.2. iLet bihormonal bionic pancreas 3.5.3. Glucose nanosensors 3.5.4. Beta cell replacement therapy 3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes 3.6.1.2. Rise in healthcare expenditure & disposable income 3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains 3.6.2.2. Lack of awareness 3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs 3.6.3.2. High undiagnosed diabetic patient population

CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends 4.2.2. Key growth factors and opportunities 4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends 4.3.2. Key growth factors and opportunities 4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends 4.4.2. Key growth factors and opportunities 4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends 4.5.2. Key growth factors and opportunities 4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends 4.6.2. Key growth factors and opportunities 4.6.3. Market size and forecast

CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (14YEARS)

5.3.1. Market size and forecast

CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. INTENSIVE CARE UNITS (ICU)

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview 8.1.2. Company snapshot 8.1.3. Operating business segments 8.1.4. Product portfolio 8.1.5. Business performance 8.1.6. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Company overview 8.2.2. Company snapshot 8.2.3. Product portfolio 8.2.4. Business performance 8.2.5. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Company overview 8.3.2. Company snapshot 8.3.3. Operating business segments 8.3.4. Product portfolio

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Company overview 8.4.2. Company snapshot 8.4.3. Operating business segments 8.4.4. Product portfolio 8.4.5. Business performance 8.4.6. Key strategic moves and developments

8.5. GLYSENS INCORPORATED

8.5.1. Company overview 8.5.2. Company snapshot 8.5.3. Product portfolio 8.5.4. Key strategic moves and developments

8.6. MANNKIND CORPORATION

8.6.1. Company overview 8.6.2. Company snapshot 8.6.3. Operating business segments 8.6.4. Product portfolio 8.6.5. Business performance

8.7. MEDTRONIC PLC.

8.7.1. Company overview 8.7.2. Company snapshot 8.7.3. Operating business segments 8.7.4. Product portfolio 8.7.5. Business performance 8.7.6. Key strategic moves and developments

8.8. NOVO NORDISK A/S

8.8.1. Company overview 8.8.2. Company snapshot 8.8.3. Operating business segments 8.8.4. Product portfolio 8.8.5. Business performance

8.9. SANOFI

8.9.1. Company overview 8.9.2. Company snapshot 8.9.3. Operating business segments 8.9.4. Product portfolio 8.9.5. Business performance 8.9.6. Key strategic moves and developments

8.10. SENSEONICS HOLDINGS, INC.

8.10.1. Company overview 8.10.2. Company snapshot 8.10.3. Operating business segments 8.10.4. Product portfolio 8.10.5. Business performance 8.10.6. Key strategic moves and developments

Check for discount @ https://www.kdmarketresearch.com/discount/3441

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

 Contact us - KD Market Research

150 State Street, Albany,

New York, USA 12207

Email id  sales@kdmarketresearch.com

[frontstreet1]

U.S. Stocks Edge Higher As Health Care Companies Rise

FILE - In this Wednesday, Oct. 8, 2014, file photo, a statue of George Washington stands near the New York Stock Exchange, in background. U.S. stocks are lower early Thursday, Sept. 28, 2017, as technology companies decline and smaller companies slip after a rally brought them to record highs. Drug and medical device maker Abbott Laboratories is climbing after regulators approved its new blood glucose monitoring system for diabetes patients. Energy companies are higher as the price of oil rises. (AP Photo/Mark Lennihan, File)

NEW YORK — U.S. stocks are slightly higher Thursday as health care companies rise. AbbVie jumped after it reached a deal with a competitor that would delay competition for its anti-inflammatory treatment Humira, the biggest-selling drug in the world. Technology companies and banks are also up.

KEEPING SCORE: The Standard & Poor’s 500 index rose 2 points, or 0.1 percent, to 2,509 as of 3:15 p.m. Eastern time. The Dow Jones industrial average rose 47 points, or 0.2 percent, to 22,388. The Nasdaq composite shed 3 points, or 0.1 percent, to 6,449. The Russell 2000 index of smaller-company stocks rose 4 points, or 0.3 percent, to 1,488. The Russell 2000 is at all-time highs and is coming off its biggest daily gain in six months.

September is historically a weak month for stocks, as the S&P 500 falls about 0.5 percent in September on average. But the index is up 1.5 percent this month, on track for its sixth consecutive monthly gain.

HEALTH CARE GAINS: Drugmaker AbbVie climbed after it resolved a patent dispute over Amgen’s version of AbbVie’s drug Humira, which is the source of most of its revenue. Amgen agreed not to begin selling its version of the anti-inflammatory medicine in Europe until October 2018, and the U.S. version won’t go on the market until Jan. 31, 2023.

The settlement would mean billions of dollars in additional sales for AbbVie, which reported $16 billion in Humira sales in 2016. Its stock gained $4.59, or 5.4 percent, to $89.34 and Amgen rose 30 cents to $185.18.

ABBOTT APPROVAL: Abbott Laboratories jumped after the Food and Drug Administration approved its FreeStyle Libre Flash glucose monitoring system for adults with Type 1 diabetes. The product uses a sensor inserted below the skin to measure blood glucose. Analysts say Abbott could have a competitive edge because the FDA did not advise patients to take samples of their blood to confirm the system’s readings.

Abbott rose $1.51, or 2.9 percent, to $53.66. DexCom, which gets all its revenue from selling its own blood glucose monitoring system, plunged $22.70, or 33.6 percent, to $44.77 in heavy trading.

OIL: Benchmark U.S. crude gave up an early gain and fell 58 cents, or 1.1 percent, to $51.56 a barrel in New York. Brent crude, the standard for international oil prices, fell 49 cents to $57.41 per barrel in London.

Wholesale gasoline lost 2 cents to $1.63 a gallon. Heating oil fell 1 cent to $1.83 a gallon. Natural gas slid 4 cents to $3.02 per 1,000 cubic feet.

WELL SEASONED: Spice maker McCormick raised its profit and revenue estimates after it beat expectations in the fiscal third quarter. Its stock gained $4.89, or 5.1 percent, to $101.35.

BREWING UP CHANGE: Tea and seasonings maker Hain Celestial Group jumped after the company appointed six new members to its board after talks with investor Engaged Capital. That means directors backed by Engaged will make up a majority on the board, as three of Hain’s current directors will leave the board in November. Hain Celestial rose 48 cents, or 1.2 percent, to $40.91.

RITE AID GOES WRONG: Drugstore chain Rite Aid dropped after its quarterly revenue fell short of Wall Street’s forecasts. The stock lost 26 cents, or 11.2 percent, to $2.03. Earlier this month the company agreed to sell almost half of its stores to rival Walgreens for $4.38 billion, but the slimmed-down deal was smaller than investors had hoped.

BONDS: Bond prices rebounded from an early slump. The yield on the 10-year Treasury note remained at 2.31 percent.

METALS: Gold inched up 90 cents to $1,288.70 an ounce. Silver added 2 cents to $16.85 an ounce. Copper rose 5 cents to $2.98 a pound.

CURRENCIES: The dollar dipped to 112.41 yen from 112.75 yen. The euro rose to $1.1789 from $1.1756.

OVERSEAS: The German DAX gained 0.4 percent and the CAC 40 in France rose 0.2 percent. In Britain the FTSE 100 added 0.1 percent. Japan’s Nikkei index rose 0.5 percent and in South Korea the Kospi made a tiny gain. Hong Kong’s Hang Seng index slipped 0.8 percent.

By MARLEY JAY - Sep 28 3:40 PM EDT

___

AP Markets Writer Marley Jay can be reached at http://twitter.com/MarleyJayAP His work can be found at https://apnews.com/search/marley%20jay